Review



bnt162b2 monovalent xbb.1.5  (BioNTech)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    BioNTech bnt162b2 monovalent xbb.1.5
    Bnt162b2 Monovalent Xbb.1.5, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bnt162b2 monovalent xbb.1.5/product/BioNTech
    Average 90 stars, based on 1 article reviews
    bnt162b2 monovalent xbb.1.5 - by Bioz Stars, 2026-02
    90/100 stars

    Images



    Similar Products

    bnt162b2 monovalent xbb.1.5  (BioNTech)
    90
    BioNTech bnt162b2 monovalent xbb.1.5
    Bnt162b2 Monovalent Xbb.1.5, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bnt162b2 monovalent xbb.1.5/product/BioNTech
    Average 90 stars, based on 1 article reviews
    bnt162b2 monovalent xbb.1.5 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    monovalent omicron xbb.1.5-adapted bnt162b2 covid-19 vaccine  (Pfizer Inc)
    90
    Pfizer Inc monovalent omicron xbb.1.5-adapted bnt162b2 covid-19 vaccine
    Monovalent Omicron Xbb.1.5 Adapted Bnt162b2 Covid 19 Vaccine, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monovalent omicron xbb.1.5-adapted bnt162b2 covid-19 vaccine/product/Pfizer Inc
    Average 90 stars, based on 1 article reviews
    monovalent omicron xbb.1.5-adapted bnt162b2 covid-19 vaccine - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    bnt162b2 xbb.1.5-adapted mrna covid-19 vaccine  (BioNTech)
    90
    BioNTech bnt162b2 xbb.1.5-adapted mrna covid-19 vaccine
    Vaccine effectiveness against JN.1-related hospitalisation in SARI patients who received at least one dose of <t>BNT162b2</t> XBB vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season
    Bnt162b2 Xbb.1.5 Adapted Mrna Covid 19 Vaccine, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bnt162b2 xbb.1.5-adapted mrna covid-19 vaccine/product/BioNTech
    Average 90 stars, based on 1 article reviews
    bnt162b2 xbb.1.5-adapted mrna covid-19 vaccine - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    xbb.1.5 mrna vaccine bnt162b2  (BioNTech)
    90
    BioNTech xbb.1.5 mrna vaccine bnt162b2
    Vaccine effectiveness against JN.1-related hospitalisation in SARI patients who received at least one dose of <t>BNT162b2</t> XBB vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season
    Xbb.1.5 Mrna Vaccine Bnt162b2, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/xbb.1.5 mrna vaccine bnt162b2/product/BioNTech
    Average 90 stars, based on 1 article reviews
    xbb.1.5 mrna vaccine bnt162b2 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    bnt162b2 xbb.1.5 vaccine  (BioNTech)
    90
    BioNTech bnt162b2 xbb.1.5 vaccine
    Vaccine effectiveness against JN.1-related hospitalisation in SARI patients who received at least one dose of <t>BNT162b2</t> XBB vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season
    Bnt162b2 Xbb.1.5 Vaccine, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bnt162b2 xbb.1.5 vaccine/product/BioNTech
    Average 90 stars, based on 1 article reviews
    bnt162b2 xbb.1.5 vaccine - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    updated bnt162b2 omicron xbb.1.5 vaccine  (BioNTech)
    90
    BioNTech updated bnt162b2 omicron xbb.1.5 vaccine
    A – F Neutralization assessment for pseudo-typed particles with plasma post <t>BNT162b2</t> XBB.1.5 vaccination. Each mutant shown contains a single mutation reverting the amino acid mutation in BA.2.86 to the corresponding amino acid within BA.2. Particles pseudo-typed with the indicated S proteins were pre-incubated for one hour at 37 °C with plasma dilutions from double boostered health care workers. Pseudo-virus neutralization titer 50 (PVNT50) was calculated using the least squares fit using a variable slope, using a four-parameter nonlinear regression model. The lower limit of confidence (LLOC) was set at a PVNT50 of 50. Non responders are defined as individuals below this 60 (dashed line). All PVNT50 below 10 are set at 10 for visualization purposes. The assay was performed in technical duplicates and with negative controls to assess the virus input of each used pseudo-virus in the absence of plasma antibodies. Statistical significance was assessed by Friedman two sided nonparametric paired test (ns, p > 0.05; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001). Source data are provided as a Source Data file.
    Updated Bnt162b2 Omicron Xbb.1.5 Vaccine, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/updated bnt162b2 omicron xbb.1.5 vaccine/product/BioNTech
    Average 90 stars, based on 1 article reviews
    updated bnt162b2 omicron xbb.1.5 vaccine - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    bnt162b2 omicron xbb.1.5 raxtozinameran  (BioNTech)
    90
    BioNTech bnt162b2 omicron xbb.1.5 raxtozinameran
    ( A , B ) Concentrations of Wuhan-Hu-1 S-specific IgG and Omicron S-specific IgG in plasma of all LTRs ( n = 34) taken before and after vaccination with <t>BNT162b2</t> Omicron XBB.1.5 vaccine or after vaccination and infection. ( C , D ) Concentrations of Wuhan-Hu-1 S-specific IgG and Omicron S-specific IgG in plasma in all LTRs with sole vaccination taken before and after vaccination with BNT162b2 Omicron XBB.1.5 vaccine ( n = 28). ( E , F ) Concentrations of Wuhan-Hu-1 S-specific IgG and Omicron S-specific IgG in plasma in LTRs with breakthrough infection shortly after vaccination taken before vaccination with BNT162b2 Omicron XBB.1.5 vaccine and after vaccination and infection ( n = 6). Paired T-test performed statistical significance (*** = p < 0.001). Red dots represent individual LTRs, grey lines connect paired data points for the same LTR. Abbreviations: IgG: immunoglobulin G; Vac: vaccination; S: spike.
    Bnt162b2 Omicron Xbb.1.5 Raxtozinameran, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bnt162b2 omicron xbb.1.5 raxtozinameran/product/BioNTech
    Average 90 stars, based on 1 article reviews
    bnt162b2 omicron xbb.1.5 raxtozinameran - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    bnt162b2 xbb.1.5-adapted mrna vaccine  (BioNTech)
    90
    BioNTech bnt162b2 xbb.1.5-adapted mrna vaccine
    Characteristics of study participants according to receipt of <t> BNT162b2 </t> XBB.1.5-adapted vaccine and SARS-CoV-2 case classification.
    Bnt162b2 Xbb.1.5 Adapted Mrna Vaccine, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bnt162b2 xbb.1.5-adapted mrna vaccine/product/BioNTech
    Average 90 stars, based on 1 article reviews
    bnt162b2 xbb.1.5-adapted mrna vaccine - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    bnt162b2 omi xbb.1.5  (Pfizer Inc)
    90
    Pfizer Inc bnt162b2 omi xbb.1.5
    Representative completed and ongoing clinical studies (immunotherapy)
    Bnt162b2 Omi Xbb.1.5, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bnt162b2 omi xbb.1.5/product/Pfizer Inc
    Average 90 stars, based on 1 article reviews
    bnt162b2 omi xbb.1.5 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Vaccine effectiveness against JN.1-related hospitalisation in SARI patients who received at least one dose of BNT162b2 XBB vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season

    Journal: medRxiv

    Article Title: Durability of the BNT162b2 XBB.1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform

    doi: 10.1101/2025.05.02.25326904

    Figure Lengend Snippet: Vaccine effectiveness against JN.1-related hospitalisation in SARI patients who received at least one dose of BNT162b2 XBB vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season

    Article Snippet: Since its authorisation by the European Medicines Agency (EMA) on 30 August 2023 [ ], numerous real-world studies have reported on the vaccine effectiveness (VE) of the BNT162b2 XBB.1.5-adapted mRNA COVID-19 vaccine (Pfizer/BioNTech 2023–2024 formulation, hereafter referred to as the BNT162b2 XBB vaccine) during the 2023–2024 season [ – ].

    Techniques:

    Journal: medRxiv

    Article Title: Durability of the BNT162b2 XBB.1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform

    doi: 10.1101/2025.05.02.25326904

    Figure Lengend Snippet:

    Article Snippet: Since its authorisation by the European Medicines Agency (EMA) on 30 August 2023 [ ], numerous real-world studies have reported on the vaccine effectiveness (VE) of the BNT162b2 XBB.1.5-adapted mRNA COVID-19 vaccine (Pfizer/BioNTech 2023–2024 formulation, hereafter referred to as the BNT162b2 XBB vaccine) during the 2023–2024 season [ – ].

    Techniques:

    Spline-based vaccine effectiveness by time since dose against JN.1-related hospitalisation among SARI patients who received at least one dose of BNT162b2 XBB vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season.

    Journal: medRxiv

    Article Title: Durability of the BNT162b2 XBB.1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform

    doi: 10.1101/2025.05.02.25326904

    Figure Lengend Snippet: Spline-based vaccine effectiveness by time since dose against JN.1-related hospitalisation among SARI patients who received at least one dose of BNT162b2 XBB vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season.

    Article Snippet: Since its authorisation by the European Medicines Agency (EMA) on 30 August 2023 [ ], numerous real-world studies have reported on the vaccine effectiveness (VE) of the BNT162b2 XBB.1.5-adapted mRNA COVID-19 vaccine (Pfizer/BioNTech 2023–2024 formulation, hereafter referred to as the BNT162b2 XBB vaccine) during the 2023–2024 season [ – ].

    Techniques:

    Vaccine effectiveness against JN.1-related hospitalisation in SARI patients who received at least one dose of BNT162b2 XBB vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter, with durability stratified by age group.

    Journal: medRxiv

    Article Title: Durability of the BNT162b2 XBB.1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform

    doi: 10.1101/2025.05.02.25326904

    Figure Lengend Snippet: Vaccine effectiveness against JN.1-related hospitalisation in SARI patients who received at least one dose of BNT162b2 XBB vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter, with durability stratified by age group.

    Article Snippet: Since its authorisation by the European Medicines Agency (EMA) on 30 August 2023 [ ], numerous real-world studies have reported on the vaccine effectiveness (VE) of the BNT162b2 XBB.1.5-adapted mRNA COVID-19 vaccine (Pfizer/BioNTech 2023–2024 formulation, hereafter referred to as the BNT162b2 XBB vaccine) during the 2023–2024 season [ – ].

    Techniques:

    Vaccine effectiveness against JN.1-related hospitalisation in SARI patients who received at least one dose of BNT162b2 XBB vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter, with durability stratified by number of chronic conditions.

    Journal: medRxiv

    Article Title: Durability of the BNT162b2 XBB.1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform

    doi: 10.1101/2025.05.02.25326904

    Figure Lengend Snippet: Vaccine effectiveness against JN.1-related hospitalisation in SARI patients who received at least one dose of BNT162b2 XBB vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter, with durability stratified by number of chronic conditions.

    Article Snippet: Since its authorisation by the European Medicines Agency (EMA) on 30 August 2023 [ ], numerous real-world studies have reported on the vaccine effectiveness (VE) of the BNT162b2 XBB.1.5-adapted mRNA COVID-19 vaccine (Pfizer/BioNTech 2023–2024 formulation, hereafter referred to as the BNT162b2 XBB vaccine) during the 2023–2024 season [ – ].

    Techniques:

    A – F Neutralization assessment for pseudo-typed particles with plasma post BNT162b2 XBB.1.5 vaccination. Each mutant shown contains a single mutation reverting the amino acid mutation in BA.2.86 to the corresponding amino acid within BA.2. Particles pseudo-typed with the indicated S proteins were pre-incubated for one hour at 37 °C with plasma dilutions from double boostered health care workers. Pseudo-virus neutralization titer 50 (PVNT50) was calculated using the least squares fit using a variable slope, using a four-parameter nonlinear regression model. The lower limit of confidence (LLOC) was set at a PVNT50 of 50. Non responders are defined as individuals below this 60 (dashed line). All PVNT50 below 10 are set at 10 for visualization purposes. The assay was performed in technical duplicates and with negative controls to assess the virus input of each used pseudo-virus in the absence of plasma antibodies. Statistical significance was assessed by Friedman two sided nonparametric paired test (ns, p > 0.05; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001). Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Reverse mutational scanning of SARS-CoV-2 spike BA.2.86 identifies epitopes contributing to immune escape from polyclonal sera

    doi: 10.1038/s41467-025-55871-5

    Figure Lengend Snippet: A – F Neutralization assessment for pseudo-typed particles with plasma post BNT162b2 XBB.1.5 vaccination. Each mutant shown contains a single mutation reverting the amino acid mutation in BA.2.86 to the corresponding amino acid within BA.2. Particles pseudo-typed with the indicated S proteins were pre-incubated for one hour at 37 °C with plasma dilutions from double boostered health care workers. Pseudo-virus neutralization titer 50 (PVNT50) was calculated using the least squares fit using a variable slope, using a four-parameter nonlinear regression model. The lower limit of confidence (LLOC) was set at a PVNT50 of 50. Non responders are defined as individuals below this 60 (dashed line). All PVNT50 below 10 are set at 10 for visualization purposes. The assay was performed in technical duplicates and with negative controls to assess the virus input of each used pseudo-virus in the absence of plasma antibodies. Statistical significance was assessed by Friedman two sided nonparametric paired test (ns, p > 0.05; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001). Source data are provided as a Source Data file.

    Article Snippet: All participants donated blood directly prior to vaccination with 30 μg of the updated BNT162b2 Omicron XBB.1.5 vaccine (Raxtozinameran, BioNTech, Mainz, Germany) in September 2023 and were followed-up for another blood collection 15–16 days post vaccination .

    Techniques: Neutralization, Clinical Proteomics, Mutagenesis, Incubation, Virus

    ( A , B ) Concentrations of Wuhan-Hu-1 S-specific IgG and Omicron S-specific IgG in plasma of all LTRs ( n = 34) taken before and after vaccination with BNT162b2 Omicron XBB.1.5 vaccine or after vaccination and infection. ( C , D ) Concentrations of Wuhan-Hu-1 S-specific IgG and Omicron S-specific IgG in plasma in all LTRs with sole vaccination taken before and after vaccination with BNT162b2 Omicron XBB.1.5 vaccine ( n = 28). ( E , F ) Concentrations of Wuhan-Hu-1 S-specific IgG and Omicron S-specific IgG in plasma in LTRs with breakthrough infection shortly after vaccination taken before vaccination with BNT162b2 Omicron XBB.1.5 vaccine and after vaccination and infection ( n = 6). Paired T-test performed statistical significance (*** = p < 0.001). Red dots represent individual LTRs, grey lines connect paired data points for the same LTR. Abbreviations: IgG: immunoglobulin G; Vac: vaccination; S: spike.

    Journal: Viruses

    Article Title: Immune Response to SARS-CoV-2 XBB.1.5 and JN.1 Variants Following XBB.1.5 Booster Vaccination in Liver Transplant Recipients

    doi: 10.3390/v16121942

    Figure Lengend Snippet: ( A , B ) Concentrations of Wuhan-Hu-1 S-specific IgG and Omicron S-specific IgG in plasma of all LTRs ( n = 34) taken before and after vaccination with BNT162b2 Omicron XBB.1.5 vaccine or after vaccination and infection. ( C , D ) Concentrations of Wuhan-Hu-1 S-specific IgG and Omicron S-specific IgG in plasma in all LTRs with sole vaccination taken before and after vaccination with BNT162b2 Omicron XBB.1.5 vaccine ( n = 28). ( E , F ) Concentrations of Wuhan-Hu-1 S-specific IgG and Omicron S-specific IgG in plasma in LTRs with breakthrough infection shortly after vaccination taken before vaccination with BNT162b2 Omicron XBB.1.5 vaccine and after vaccination and infection ( n = 6). Paired T-test performed statistical significance (*** = p < 0.001). Red dots represent individual LTRs, grey lines connect paired data points for the same LTR. Abbreviations: IgG: immunoglobulin G; Vac: vaccination; S: spike.

    Article Snippet: We prospectively analyzed 34 adult LTRs who received a 30 μg dose of BNT162b2 Omicron XBB.1.5 (Raxtozinameran, BioNtech, Mainz, Germany) booster vaccination at the University Medical Center Hamburg-Eppendorf between September 2023 and January 2024.

    Techniques: Clinical Proteomics, Infection

    Characteristics of study participants according to receipt of BNT162b2 XBB.1.5-adapted vaccine and SARS-CoV-2 case classification.

    Journal: eClinicalMedicine

    Article Title: Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platform

    doi: 10.1016/j.eclinm.2024.102995

    Figure Lengend Snippet: Characteristics of study participants according to receipt of BNT162b2 XBB.1.5-adapted vaccine and SARS-CoV-2 case classification.

    Article Snippet: On 31 August 2023, the European Medicines Agency (EMA) authorized BNT162b2 XBB.1.5-adapted mRNA vaccine (Pfizer/BioNTech Manufacturing GmbH 2023–2024 formulation; hereafter referred to as BNT162b2 XBB vaccine) for the prevention of coronavirus disease 2019 (COVID-19) in individuals 6 months of age and older for the 2023–2024 autumn/winter season.

    Techniques: Infection

    Vaccine effectiveness 1 against COVID-19 hospitalization in SARI patients who received at least one dose of BNT162b2 XBB.1.5-adapted vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season. 1 Vaccine effectiveness estimates are adjusted for date of symptom onset, age, sex, and number of chronic conditions. 2 ‘Never vaccinated’ subjects were excluded when calculating the median (IQR) of time since last vaccine dose in the unexposed group (patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season). 3 The categories “Cancer” and “Immunodeficiency” among chronic conditions are counted as separate types of chronic conditions in all adjusted VE estimates. Here, the VE estimate among participants having “Immunodeficiency or cancer” is provided as a composite. 4 The categories “0” and “1” among the number of chronic conditions are counted as separate categories of number of chronic conditions in all adjusted VE estimates. Here, the VE estimate among participants having “0–1”chronic conditions is provided as a composite.

    Journal: eClinicalMedicine

    Article Title: Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platform

    doi: 10.1016/j.eclinm.2024.102995

    Figure Lengend Snippet: Vaccine effectiveness 1 against COVID-19 hospitalization in SARI patients who received at least one dose of BNT162b2 XBB.1.5-adapted vaccine compared to patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season. 1 Vaccine effectiveness estimates are adjusted for date of symptom onset, age, sex, and number of chronic conditions. 2 ‘Never vaccinated’ subjects were excluded when calculating the median (IQR) of time since last vaccine dose in the unexposed group (patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season). 3 The categories “Cancer” and “Immunodeficiency” among chronic conditions are counted as separate types of chronic conditions in all adjusted VE estimates. Here, the VE estimate among participants having “Immunodeficiency or cancer” is provided as a composite. 4 The categories “0” and “1” among the number of chronic conditions are counted as separate categories of number of chronic conditions in all adjusted VE estimates. Here, the VE estimate among participants having “0–1”chronic conditions is provided as a composite.

    Article Snippet: On 31 August 2023, the European Medicines Agency (EMA) authorized BNT162b2 XBB.1.5-adapted mRNA vaccine (Pfizer/BioNTech Manufacturing GmbH 2023–2024 formulation; hereafter referred to as BNT162b2 XBB vaccine) for the prevention of coronavirus disease 2019 (COVID-19) in individuals 6 months of age and older for the 2023–2024 autumn/winter season.

    Techniques:

    Vaccine effectiveness 1 against COVID-19 hospitalization in SARI patients who received at least one dose of BNT162b2 XBB.1.5-adapted vaccine using various prior vaccination categories as reference groups. 1 Vaccine effectiveness estimates are adjusted for date of symptom onset, age, sex, and number of chronic conditions. 2 ‘Never vaccinated’ subjects were excluded when calculating the median (IQR) of time since last vaccine dose among patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season. 3 Stratifications of comparison groups were assessed on matched data per exposure of interest and numbers will therefore not add up to the numbers provided in <xref ref-type=Table 1 . Patient characteristics of these subsets are shown in Supplementary Table S3 . " width="100%" height="100%">

    Journal: eClinicalMedicine

    Article Title: Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platform

    doi: 10.1016/j.eclinm.2024.102995

    Figure Lengend Snippet: Vaccine effectiveness 1 against COVID-19 hospitalization in SARI patients who received at least one dose of BNT162b2 XBB.1.5-adapted vaccine using various prior vaccination categories as reference groups. 1 Vaccine effectiveness estimates are adjusted for date of symptom onset, age, sex, and number of chronic conditions. 2 ‘Never vaccinated’ subjects were excluded when calculating the median (IQR) of time since last vaccine dose among patients who did not receive any dose of a COVID-19 vaccine in the 2023–2024 autumn/winter season. 3 Stratifications of comparison groups were assessed on matched data per exposure of interest and numbers will therefore not add up to the numbers provided in Table 1 . Patient characteristics of these subsets are shown in Supplementary Table S3 .

    Article Snippet: On 31 August 2023, the European Medicines Agency (EMA) authorized BNT162b2 XBB.1.5-adapted mRNA vaccine (Pfizer/BioNTech Manufacturing GmbH 2023–2024 formulation; hereafter referred to as BNT162b2 XBB vaccine) for the prevention of coronavirus disease 2019 (COVID-19) in individuals 6 months of age and older for the 2023–2024 autumn/winter season.

    Techniques: Comparison

    Representative completed and ongoing clinical studies (immunotherapy)

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications

    doi: 10.1038/s41392-024-02002-z

    Figure Lengend Snippet: Representative completed and ongoing clinical studies (immunotherapy)

    Article Snippet: BNT162b2 (Omi XBB.1.5) + RIV , COVID-19 and influenza , 2024-01-31 , Phase II , Active, not recruiting , Pfizer , NCT06237049.

    Techniques: Virus, Injection, Membrane, Immunopeptidomics, Adjuvant, Activity Assay, Plasmid Preparation, Saline, Electroporation, Transfection, Inhibition

    Clinical trials were conducted according to different age groups

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications

    doi: 10.1038/s41392-024-02002-z

    Figure Lengend Snippet: Clinical trials were conducted according to different age groups

    Article Snippet: BNT162b2 (Omi XBB.1.5) + RIV , COVID-19 and influenza , 2024-01-31 , Phase II , Active, not recruiting , Pfizer , NCT06237049.

    Techniques: Clinical Proteomics

    Ongoing and completed clinical trials of mRNA vaccines for the treatment of immunosuppressant patients/patients with autoimmune diseases

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications

    doi: 10.1038/s41392-024-02002-z

    Figure Lengend Snippet: Ongoing and completed clinical trials of mRNA vaccines for the treatment of immunosuppressant patients/patients with autoimmune diseases

    Article Snippet: BNT162b2 (Omi XBB.1.5) + RIV , COVID-19 and influenza , 2024-01-31 , Phase II , Active, not recruiting , Pfizer , NCT06237049.

    Techniques: Clinical Proteomics, Vaccines, Tandem Mass Spectroscopy

    Concurrently administered vaccines

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications

    doi: 10.1038/s41392-024-02002-z

    Figure Lengend Snippet: Concurrently administered vaccines

    Article Snippet: BNT162b2 (Omi XBB.1.5) + RIV , COVID-19 and influenza , 2024-01-31 , Phase II , Active, not recruiting , Pfizer , NCT06237049.

    Techniques: Infection